A protein called POP2 inhibits a key inflammatory pathway, calming the body’s inflammatory response before it can become destructive, Northwestern Medicine scientists have demonstrated in mouse models.
The study, published in the journal Nature Communications, adds to the understanding of how the body maintains a balanced inflammatory response and could have important implications in the development of future therapies for inflammatory diseases.
“We found these proteins nine years ago, but all the research was done in cell studies, so we weren’t sure if it had a function with inflammation in vivo. This study now shows that POP2 really has a profound impact on dampening these responses,” said senior author Christian Stehlik, PhD, the John P. Gallagher Research Professor of Rheumatology.
Andrea Dorfleutner, PhD, research associate professor of Medicine in the Division of Rheumatology, was also a senior author of the study. Rojo Ratsimandresy, PhD, a postdoctoral fellow in Stehlik’s lab, was the first author. He will join Feinberg’s faculty as a research assistant professor of Medicine in the Division of Rheumatology in September.
POP2 is one of three members of the PYRIN domain-only family of proteins, which was discovered by Stehlik’s laboratory. Over the last decade, his research has largely focused on these proteins — POP1, POP2 and POP3 — and their role in resolving inflammatory responses.
Specifically, the three proteins each act on unique types of inflammasomes — protein complexes that release pro-inflammatory cytokines — in order to tightly control the inflammatory process and prevent systemic inflammation after an initial response.
In the current study, the scientists demonstrated that POP2 is distinctive among the family of PYRIN domain-only proteins in performing two essential functions in vivo: “POP2 both blocks inflammasomes and inhibits NF-κB, a pro-inflammatory transcription factor that leads to the initial priming of inflammasome responses,” Dorfleutner said.
“Together, these two activities inhibit the inflammatory response — and that’s why POP2 is probably so potent,” explained Stehlik, also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Because mice lack the genes for the PYRIN domain-only proteins, the scientists engineered mice to express human POP2, using a promoter that drives expression of the protein in immune cells called macrophages. These cells are important for sensing tissue damage and infections.
“We found that only expressing this protein in this one particular cell type can, in vivo, completely ameliorate these inflammatory responses,” Stehlik said.
The scientists further showed, in cell culture studies, that a synthetic version of POP2 added to healthy macrophages blocked the same inflammatory pathway, similar to when the protein is expressed in cells. Ongoing research is now working to optimize cellular delivery, with the goal of bringing synthetic POP2 to preclinical mouse models.
The Northwestern team has previously demonstrated that synthetic versions of POP1 injected into mice significantly dampen inflammation.
“The hope is that eventually it can be used to target the increasing number of inflammatory conditions in humans,” Stehlik said.
The paper was also co-authored by Harris Perlman, PhD, chief of Rheumatology in the Department of Medicine and Mabel Greene Myers Professor of Medicine; Lucia Maria De Almeida, PhD, research assistant professor of Medicine in the Division of Rheumatology; Mohanalaxmi Indramohan, PhD, a postdoctoral fellow in the Stehlik lab; and Lan Chu and Anu Gangopadhyay, both students in the Driskill Graduate Program in Life Sciences (DGP). Collaborators included Sonal Khare, PhD, a former research assistant professor of Medicine in the Division of Rheumatology and currently a group leader at Jubilant Biosys Ltd., Alexander Misharin, MD, PhD, assistant professor of Medicine in the Division of Pulmonary and Critical Care and David Greaves, PhD, professor at the University of Oxford.
The research was supported by the National Institutes of Health grants AI099009, AR064349, AI120618, AI120625, AR066739, T32AR007611 and AR064349S1, Cancer Center Support Grant CA060553, the Skin Disease Research Center grant AR057216, the British Heart Foundation RG/15/10/31485, the Vietnam Education Foundation Fellowship, the American Heart Association 15PRE25700116, 11POST585000 and 15POST25690052, and the Arthritis Foundation AF161715.
